DMAC News and Press, DiaMedica Therapeutics Inc. From 04/15/25

2025-04-15 20:54:24 ET Summary DiaMedica Therapeutics is developing DM199 for acute ischemic stroke and preeclampsia, with promising AIS clinical trial progress and Fast Track Designation by the FDA. DM199 aims to extend the treatment window for AIS to 24 hours, potentially benefi...

2025-04-06 20:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-03-18 10:27:40 ET DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Conference Call March 18, 2025, 08:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conference Call Participants Thomas Fl...

2025-03-17 16:33:53 ET More on DiaMedica Therapeutics DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke Seeking Alpha’s Quant Rating on DiaMedica Therapeutics Historical earnings data for DiaMedica Therapeutics Financial information ...

Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoi...

Eyenovia Inc. (EYEN) is expected to report $-8 for Q4 2024 Nemaura Medical Inc. (NMRD) is expected to report for quarter end 2024-12-31 LanzaTech Global Inc. (LNZA) is expected to report $-0.16 for Q4 2024 Investcorp Credit Management BDC Inc. (ICMB) is expected to report for Q2 2025 ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17 th . DiaMedica wil...

2025-03-06 07:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O’Connor to its Board of Directors, effective February 20, 2025. Mr. O’Connor has decades of execut...

2025-02-23 23:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...